Three months af­ter big re­or­ga­ni­za­tion, an­ti­body mak­er Atre­ca is back with an­oth­er round of lay­offs

Atre­ca is let­ting an­oth­er 40% of its staff go in a move ex­pect­ed to keep it­self afloat through the first quar­ter of 2024 as it ex­plores strate­gic al­ter­na­tives.

The biotech is fo­cused on ad­vanc­ing APN-497444, an an­ti­body-drug con­ju­gate tar­get­ing a tu­mor-spe­cif­ic gly­can, through pre­clin­i­cal test­ing. Its fund­ing needs for that pro­gram and oth­er fol­low-up AD­Cs, cou­pled with cur­rent fi­nan­cial mar­ket con­di­tions, led to the de­ci­sion, Atre­ca CEO John Or­win said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.